Head-to-head · WeighScore
Bodybuilding Health+ vs MultiMedRx
The verdict
Bodybuilding Health+ takes it — 78.1/100 to 57.6/100.
Bodybuilding Health+ grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The Bodybuilding.com fitness brand's new compounded-telehealth arm — genuinely cheap GLP-1 bundles (sema and tirz both down to $139/mo on the annual plan) sitting on top of a deep sermorelin/NAD+/peptide bench — solid value and honest FDA labeling, but brand-new, compounded, and final-sale, so it lands as a value runner-up rather than a top pick.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bodybuilding Health+ | MultiMedRx |
|---|---|---|
| WeighScore | 78.1/100 | 57.6/100 |
| Grade | C+ | C |
| Scorecard rank | #35 | #394 |
| Semaglutide | From $139/mo | Not disclosed |
| Tirzepatide | From $139/mo | Not disclosed |
| Coverage | Not disclosed | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #35 · C+
Strengths
- Low, publicly listed bundle pricing — compounded semaglutide and tirzepatide both fall to $139/mo on the 12-month plan (first month $179 sema / $209 tirz)
- Licensed brand extension of Bodybuilding.com (trademark relationship stated on-site), which lends familiarity vs. anonymous GLP-1 startups
- Unusually broad menu under one login — GLP-1 plus NAD+ (injection or nasal), sermorelin (injection or sublingual ODT), ED/tadalafil, and a deep peptide catalog
- Standard telehealth flow with clear FDA/compounding disclaimers — online intake reviewed by independent licensed providers, U.S. compounding-pharmacy fulfillment, free until a provider approves
Where it loses points
- Compounded and not FDA-approved — not Wegovy/Ozempic or Zepbound/Mounjaro; the site itself states these have not been evaluated by the FDA for safety, effectiveness, or quality
- Brand-new operator — Dynamo Group LLC launched the storefront around April 2026 with only a thin, mixed ~26-review Trustpilot record (cancellation and billing complaints)
- All sales final — prescription products are non-returnable, the medical-consult fee is non-refundable, and there are no refunds for dissatisfaction or results
- Pharmacy and provider network aren't named on the live consumer pages, no LegitScript seal we could verify on-site, and the catalog reaches into investigational Retatrutide and research-grade peptides
Graded #394 · C
Strengths
- Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
- Two physical addresses listed: Newport Beach, CA and Reno, NV
- LegitScript seal present
- Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
- Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1
Where it loses points
- No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
- Monthly GLP-1 pricing isn't published — gated behind the consultation
- $100 consultation fee adds friction; many peers bundle it into the medication price
- Per-state availability not listed; only CA and NV offices disclosed
- Whether compounded GLP-1 is offered isn't clear — verify during intake
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.